These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 24378038)

  • 1. A review of economic impact of targeted oral anticancer medications.
    Shen C; Chien CR; Geynisman DM; Smieliauskas F; Shih YC
    Expert Rev Pharmacoecon Outcomes Res; 2014 Feb; 14(1):45-69. PubMed ID: 24378038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.
    Smieliauskas F; Chien CR; Shen C; Geynisman DM; Shih YC
    Pharmacoeconomics; 2014 Jul; 32(7):651-80. PubMed ID: 24821281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sponsorship-related outcome selection bias in published economic studies of triptans: systematic review.
    Peura PK; Martikainen JA; Purmonen TT; Turunen JH
    Med Decis Making; 2012; 32(2):237-45. PubMed ID: 21490308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Financial relationships in economic analyses of targeted therapies in oncology.
    Valachis A; Polyzos NP; Nearchou A; Lind P; Mauri D
    J Clin Oncol; 2012 Apr; 30(12):1316-20. PubMed ID: 22430267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology.
    Knox KS; Adams JR; Djulbegovic B; Stinson TJ; Tomor C; Bennet CL
    Ann Oncol; 2000 Dec; 11(12):1591-5. PubMed ID: 11205468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review.
    Jang S; Chae YK; Haddad T; Majhail NS
    Breast Cancer Res Treat; 2010 Jun; 121(2):273-9. PubMed ID: 20352486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluations of oral medications for breast cancer treatment in the U.S.: a systematic review with a focus on cost-effectiveness threshold.
    Park SK; Chun HK; Park C
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):633-643. PubMed ID: 31608715
    [No Abstract]   [Full Text] [Related]  

  • 8. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic impact of prescribing error prevention with computerized physician order entry of injectable antineoplastic drugs.
    Nerich V; Borg C; Villanueva C; Thiery-Vuillemin A; Helias P; Rohrlich PS; Demarchi M; Pivot X; Limat S
    J Oncol Pharm Pract; 2013 Mar; 19(1):8-17. PubMed ID: 22623276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations Between Industry Sponsorship and Results of Cost-effectiveness Analyses of Drugs Used in Breast Cancer Treatment.
    Lane JD; Friedberg MW; Bennett CL
    JAMA Oncol; 2016 Feb; 2(2):274-6. PubMed ID: 26658959
    [No Abstract]   [Full Text] [Related]  

  • 11. Adherence to targeted oral anticancer medications.
    Geynisman DM; Wickersham KE
    Discov Med; 2013 Apr; 15(83):231-41. PubMed ID: 23636140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disclosure of competing financial interests and role of sponsors in phase III cancer trials.
    Tuech JJ; Moutel G; Pessaux P; Thoma V; Schraub S; Herve C
    Eur J Cancer; 2005 Oct; 41(15):2237-40. PubMed ID: 16214044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to oral anticancer chemotherapies and estimation of the economic burden associated with unused medicines.
    Matti N; Delon C; Rybarczyk-Vigouret MC; Khan GM; Beck M; Michel B
    Int J Clin Pharm; 2020 Oct; 42(5):1311-1318. PubMed ID: 32857257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral Chemotherapy in Patients with Hematological Malignancies-Care Process, Pharmacoeconomic and Policy Implications.
    Betcher J; Dow E; Khera N
    Curr Hematol Malig Rep; 2016 Aug; 11(4):288-94. PubMed ID: 27086140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness research in cancer therapy: a systematic review of literature trends, methods and the influence of funding.
    Al-Badriyeh D; Alameri M; Al-Okka R
    BMJ Open; 2017 Jan; 7(1):e012648. PubMed ID: 28131999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials.
    Bennett CL; Smith TJ; George SL; Hillner BE; Fleishman S; Niell HB
    J Clin Oncol; 1995 Sep; 13(9):2457-63. PubMed ID: 7545222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomic and clinical outcomes in oncology using oral chemotherapy.
    Navarro RP; Morrow T; Baran R
    Manag Care Interface; 2002 Jul; 15(7):55-62. PubMed ID: 12143298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Economic Contribution of Industry-Sponsored Pharmaceutical Clinical Trials.
    Tran DT; Akpinar I; Fedorak R; Jonsson E; Mackey J; Richer L; Jacobs P
    J Pharm Pharm Sci; 2017; 20(1):407-414. PubMed ID: 29197429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.